Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03496012
Other study ID # 273CH301
Secondary ID 2015-003958-41
Status Completed
Phase Phase 3
First received
Last updated
Start date December 11, 2017
Est. completion date December 1, 2020

Study information

Verified date November 2023
Source Biogen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of the study is to evaluate the efficacy and safety of a single sub-retinal injection of BIIB111 in participants with choroideremia (CHM).


Description:

This study was previously posted by NightstaRx Ltd. In October 2020, sponsorship of the trial was transferred to Biogen.


Recruitment information / eligibility

Status Completed
Enrollment 169
Est. completion date December 1, 2020
Est. primary completion date December 1, 2020
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Key Inclusion Criteria: - Are willing and able to give informed consent for participation in the study. - Have a documented genetically-confirmed diagnosis of CHM. - Have active disease clinically visible within the macular region in the study eye. - Have a BCVA of 34-73 ETDRS letters (equivalent to worse than or equal to 6/12 or 20/40 Snellen acuity, but better than or equal to 6/60 or 20/200 Snellen acuity) in the study eye. Key Exclusion Criteria: - Have a history of amblyopia in the eligible eye. - Have had previous intraocular surgery performed in the study eye within 3 months of Visit 1. - Have any other significant ocular or non-ocular disease/disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the results of the study, or the participant's ability to participate in the study. - Have participated in another research study involving an investigational product in the past 12 weeks or received a gene/cell-based therapy at any time previously. - Are unwilling to use barrier contraception methods, or abstain from sexual intercourse, for a period of 3 months, if treated with AAV2-REP1. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Study Design


Related Conditions & MeSH terms


Intervention

Genetic:
BIIB111
Administered as specified in the treatment arm.

Locations

Country Name City State
Canada Research Site Montréal
Canada Research Site Vancouver
Denmark Research Site Glostrup
Finland Research Site Helsinki
France Research Site Montpellier
Germany Research Site Bonn
Germany Research Site Tübingen
Netherlands Research Site Nijmegen
United Kingdom Research Site Manchester
United Kingdom Research Site Oxford
United States Research Site Baltimore Maryland
United States Research Site Cincinnati Ohio
United States Research Site Dallas Texas
United States Research Site Los Angeles California
United States Research Site Madison Wisconsin
United States Research Site Miami Florida
United States Research Site New York New York
United States Research Site Portland Oregon

Sponsors (1)

Lead Sponsor Collaborator
Biogen

Countries where clinical trial is conducted

United States,  Canada,  Denmark,  Finland,  France,  Germany,  Netherlands,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With a =15 -Letter Improvement From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 as Measured by the Early Treatment of Diabetic Retinopathy Study (ETDRS) Chart BCVA was assessed for both eyes using the ETDRS visual acuity (VA) chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If <20 letters are read at 4 meters, testing at 1 meter should be performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of participants with a =15 -letter improvement from baseline in BCVA at Month 12 was reported for both eyes. Month 12
Secondary Change From Baseline in BCVA at Month 12 Reported as Letters Measured by the ETDRS Chart in Study Eye BCVA was assessed for study eye using the ETDRS VA chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If <20 letters are read at 4 meters, testing at 1 meter should be performed. BCVA was reported as number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Here negative values indicate decline in BCVA. Baseline, Month 12
Secondary Percentage of Participants With a =10 -Letter Improvement From Baseline in BCVA at Month 12 Measured by the ETDRS Chart BCVA was assessed for both eyes using the ETDRS VA chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If <20 letters are read at 4 meters, testing at 1 meter should be performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of participants with a =10 -letter improvement from baseline in BCVA at Month 12 was reported for both eyes. Month 12
Secondary Percentage of Participants With No Decrease From Baseline in BCVA or a Decrease From Baseline in BCVA of <5 ETDRS Letters at Month 12 Measured by the EDRS Chart BCVA was assessed for both eyes using the ETDRS VA chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If <20 letters are read at 4 meters, testing at 1 meter should be performed. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). Percentage of participants with no decrease or a decrease of <5 letters from baseline in BCVA at Month 12 was reported for both eyes. Month 12
Secondary Change From Baseline in BCVA at Months 4 and 8 Reported as Letters Measured by the ETDRS Chart BCVA was assessed for both eyes using the ETDRS VA chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If <20 letters are read at 4 meters, testing at 1 meter should be performed. BCVA was reported as number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters) in both the study and fellow eyes. The lower the number of letters read correctly on the eye chart, the worse the vision (or VA). An increase in the number of letters read correctly means that vision has improved. Here negative values indicate decline in BCVA. Baseline, Months 4 and 8
Secondary Change From Baseline in Total Area of Preserved Autofluorescence (AF) at Month 12 in Study Eye Fundus AF was used to assess change in total area of preserved AF. Areas of preserved AF were identified as well-demarcated regions of relative hyper AF compared with the background areas of surrounding atrophy. A negative change from baseline indicate decline in total area of preserved AF. Baseline, Month 12
Secondary Change From Baseline in Distance From Foveal Center to Nearest Border of Preserved AF at Month 12 in Study Eye Fundus AF was used to assess change in distance from foveal center (FC) to nearest border of preserved AF. A negative change from baseline indicate decline in distance from FC to nearest border of AF. Baseline, Month 12
Secondary Change From Baseline in the Foveal Subfield Thickness Using Spectral Domain Optical Coherence Tomography (SD-OCT) at Month 12 in Study Eye SD-OCT was used to assess change in foveal subfield thickness. The measurements were taken after dilation of the participant's pupil. A negative change from baseline indicates decline in foveal subfield thickness. Baseline, Month 12
Secondary Change From Baseline in the Total Macular Volume Using SD-OCT at Month 12 in Study Eye SD-OCT was used to assess change in total macular volume. The measurements were taken after dilation of the participant's pupil. A negative change from baseline indicates decline in total macular volume. Baseline, Month 12
Secondary Change From Baseline in the Central Horizontal Ellipsoid Width Using SD-OCT at Month 12 in Study Eye SD-OCT was used to assess change in central horizontal ellipsoid width. The measurements were taken after dilation of the participant's pupil. A negative change from baseline indicates decline in central horizontal ellipsoid width. Baseline, Month 12
Secondary Change From Baseline in the Central Ellipsoid Area Using SD-OCT at Month 12 in Study Eye SD-OCT was used to assess change in central ellipsoid area. The measurements were taken after dilation of the participant's pupil. A negative change from baseline indicates decline in central ellipsoid area. Baseline, Month 12
Secondary Change From Baseline in the Choroidal Thickness Using SD-OCT at Month 12 in Study Eye SD-OCT was used to assess change in choroidal thickness. The measurements were taken after dilation of the participant's pupil. A negative change from baseline indicates decline in choroidal thickness. Baseline, Month 12
Secondary Change From Baseline in the Mean Retinal Sensitivity Using Microperimetry at Month 12 in Study Eye Microperimetry was conducted to assess change in mean retinal sensitivity within the macula. Retinal mean sensitivity to light was measured in decibels (dBs) in multiple spots across the central and peripheral retina (entire visual field). Higher numbers (dBs) indicate higher retinal sensitivity. A negative change from baseline indicates decline in retinal sensitivity. Baseline, Month 12
Secondary Change From Baseline in the Bivariate Contour Ellipse Area 63% Using Microperimetry at Month 12 in Study Eye Microperimetry was conducted to assess change in bivariate contour ellipse area 63%. A negative change from baseline indicates decline in bivariate contour ellipse area 63%. Baseline, Month 12
Secondary Change From Baseline in the Bivariate Contour Ellipse Area 95% Using Microperimetry at Month 12 in Study Eye Microperimetry was conducted to assess change in bivariate contour ellipse area 95%. A negative change from baseline indicates decline in bivariate contour ellipse area 95%. Baseline, Month 12
Secondary Change From Baseline in Contrast Sensitivity Score at Month 12 in Study Eye Change in contrast sensitivity was assessed by Pelli-Robson chart which uses a single large letter size (20/60 optotype), with contrast varying across groups of letters (6 per line), whose contrast varies from high to low. Participants read letters, starting with highest contrast, until they are unable to read 2 or 3 letters in a single group. Each group had three letters of the same contrast level, so there were three trials per contrast level. Score is assigned based on contrast of last group in which 2 or 3 letters were correctly read. Score is a measure of participant's log contrast sensitivity ranging from 0 (no letters read) to 2.25 (all letters read). Total CS score=[(total letters correct-3) x 0.05]. A negative change from baseline indicates worsening in contrast sensitivity score. Baseline, Month 12
Secondary Change From Baseline in Colour Vision Total Error Score at Month 12 in Study Eye Colour vision total error scores were assessed by the Farnsworth Munsell 100 Hue Sort Test. Farnsworth Munsell 100 Hue Test requires placing 100 colour palettes in the correct order based upon colour hue. Scores are determined by the frequency and severity of any displacement in the correct order. One error equates to one misplaced hue, by one step or position. An error score of 0 indicates no errors in ordering the hues while error score greater than 500 indicates virtually no color discrimination. A Total Error Score of 0 to 128 could be seen in a normal population. Baseline, Month 12
Secondary Change From Baseline in Reading Speed Test at Month 12 in Study Eye The reading speed (words per minute) was calculated using the following formula: [number of words in the text - number of misread words] / reading time x 60. The number of misread words and reading time is collected. A negative change from baseline indicates decline in reading speed. Baseline, Month 12
Secondary Change From Baseline in the 25-Item Visual Function Questionnaire (VFQ-25) Composite Scores at Month 12 in Study Eye VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better functioning. Each item is then converted to a 0 to 100 scale so that the lowest and highest possible scores are set at 0 and 100 points, respectively. A score of 0 represents the worst outcome and 100 represents the best outcome. A negative change from baseline indicates decline in VFQ-25 score. Baseline, Month 12
See also
  Status Clinical Trial Phase
Completed NCT02553135 - Choroideremia Gene Therapy Clinical Trial Phase 2
Completed NCT01461213 - Gene Therapy for Blindness Caused by Choroideremia Phase 1/Phase 2
Completed NCT03507686 - A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111 Phase 2
Recruiting NCT05258032 - Structural and Functional Characterization of Rare Ocular Diseases
Recruiting NCT05282953 - A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) Phase 1/Phase 2
Withdrawn NCT05045703 - The Dark-Adapted Retinal Function Response in Choroideremia (DARC) Study N/A
Recruiting NCT01866371 - High Resolution Retinal Imaging
Completed NCT01603576 - Pilot Study of a Suprachoroidal Retinal Prosthesis N/A
Enrolling by invitation NCT03584165 - Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa Phase 3
Completed NCT03359551 - Natural History of the Progression of Choroideremia Study
Recruiting NCT02435940 - Inherited Retinal Degenerative Disease Registry
Active, not recruiting NCT04483440 - Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia Phase 1
Completed NCT02670980 - Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy N/A
Completed NCT02671539 - THOR - Tübingen Choroideremia Gene Therapy Trial Phase 2
Completed NCT02341807 - Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations Phase 1/Phase 2
Completed NCT03406416 - Study of a Suprachoroidal Retinal Prosthesis N/A
Enrolling by invitation NCT05158049 - Longitudinal Study of a Bionic Eye
Terminated NCT02994368 - "Natural History" Study of Choroideremia
Terminated NCT01654562 - The Short-term Effects of Simvastatin on the Vision of Males Affected by Choroideremia Phase 1/Phase 2
Active, not recruiting NCT00427180 - IRIS PILOT - Extended Pilot Study With a Retinal Implant System N/A